Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke

Neurology

Volumn 73, Issue 23, 2009, Pages 1957-1962

  Rost, N S ^a   Masrur, S ^a   Pervez, M A ^a   Viswanathan, A ^a   Schwamm, L H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING TENDENCY; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; DIAGNOSTIC IMAGING; DRUG CONTRAINDICATION; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; FIBRINOLYTIC THERAPY; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT CONTRAINDICATION;

EID: 73349105895     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c5b46d     Document Type: Article

References (29)

1. Adams HP, Jr., del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-1711.
2. The National Institute of Neurological Disorders and Stroke rt PASSG. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1588.
3. Kwiatkowski TG, Libman RB, Frankel M, et al. The National Institute of Neurological Disorders, Stroke Recom-binant Tissue Plasminogen Activator Stroke Study Group: effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999;340:1781-1787.
4. Wahlgren N, Ahmed N, Eriksson N, et al, for the S-MI. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Stroke 2008;39:3316-3322.
5. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. The Lancet 2007; 369:275-282.
6. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283:1145-1150.
7. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
8. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008;372:1303-1309.
9. De Keyser J, Gdovinova Z, Uyttenboogaart M, Vroomen PC, Luijckx GJ. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke 2007;38:2612-2618.
10. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: The NINDS rt-PA Stroke Study. Neurology 2000;55:1649-1655.
11. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774.
12. Lyden P. Thrombolytic therapy for acute stroke: not a moment to lose. N Engl J Med 2008;359:1393-1395.
13. Kaste M. Do not wait, act now. Stroke 2007;38:3119-3120.
14. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland Area Experience. JAMA 2000;283:1151-1158.
15. The Paul Coverdell Prototype Registries. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Cov-erdell national acute stroke registry. Stroke 2005;36:1232-1240.
16. Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol 2006;63:661-664.
17. Schestatsky P, Picon PD, Kleindorfer DO, Khatri P, Katzan I, Cocho D. Reasons for exclusion from thrombo-lytic therapy following acute ischemic stroke. Neurology 2005;65:1844.
18. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56:1015-1020.
19. Fink JN, Selim MH, Kumar S, Schlaug G, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;57:1739-1740.
20. Hills NK, Johnston SC. Why are eligible thrombolysis candidates left untreated? Am J Prev Med 2006;31:S210-S216.
21. Romano JG, Muller N, Merino JG, Forteza AM, Koch S, Rabinstein AA. In-hospital delays to stroke thrombolysis: paradoxical effect of early arrival. Neurol Res 2007;29: 664-666.
22. Huang P, Yang Y-H, Lin R-T, et al. Eligibility for recom-binant tissue plasminogen activator in acute ischemic stroke. Cerebrovasc Dis 2006;22:423-428.
23. Kwan J, Hand P, Sandercock P. A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing 2004;33:116-121. (Pubitemid 38313108)
24. Gottesman RF, Alt J, Wityk RJ, Llinas RH. Predicting abnormal coagulation in ischemic stroke: reducing delay in rt-PA use. Neurology 2006;67:1665-1667.
25. Cucchiara BL, Jackson B, Weiner M, Messe SR. Usefulness of checking platelet count before thrombolysis in acute ischemic stroke. Stroke 2007;38:1639-1640.
26. Cocho D, Belvis R, Marti-Fabregas J, et al. Reasons for exclusion from thrombolytic therapy following acute isch-emic stroke. Neurology 2005;64:719-720
27. Saver JL. Time is brain-quantified. Stroke 2006;37:263-266.
28. Genentech Inc. Activase Prescribing Information. Genen-tech Inc.: 2002.
29. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004;61:1066-1070.